

Clinical Policy: Factor IX (Human, Recombinant)

Reference Number: CP.PHAR.218

Effective Date: 05.01.16

Last Review Date: 02.22

Line of Business: Commercial, HIM, Medicaid

[Coding Implications](#)
[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

Description

The following are factor IX products requiring prior authorization: human – AlphaNine SD[®], Mononine[®]; recombinant – Alprolix[®], BeneFIX[®], Idelvion[®], Ixinity[®], Rebinyn[®], and Rixubis[®].

FDA Approved Indication(s)

Factor IX products are indicated for patients with hemophilia B (congenital factor IX deficiency or Christmas disease) for the following uses:

- Prevention and control of bleeding (on-demand treatment)
 - Adults and children: AlphaNine SD (≥ 17 years), Alprolix, BeneFIX, Idelvion, Ixinity (≥ 12 years), Mononine, Rebinyn, and Rixubis
- Perioperative management of bleeding
 - Adults and children: Alprolix, BeneFIX, Idelvion, Ixinity (≥ 12 years), Rebinyn, and Rixubis
- Routine prophylaxis to reduce the frequency of bleeding episodes
 - Adults and children: Alprolix, BeneFIX, Idelvion, Ixinity (≥ 18 years), and Rixubis

Limitation(s) of use:

- AlphaNine SD, and Mononine contain low, non-therapeutic levels of factors II, VII, and X, and, therefore, are not indicated for the treatment of factor II, VII or X deficiencies. They are also not indicated for the reversal of coumarin anticoagulant-induced hemorrhage, nor in the treatment of hemophilia A patients with inhibitors to factor VIII.
- Mononine is also not indicated in a hemorrhagic state caused by hepatitis-induced lack of production of liver dependent coagulation factors.
- Alprolix, BeneFIX, Idelvion, Ixinity, Rebinyn, and Rixubis are not indicated for induction of immune tolerance in patients with hemophilia B.

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation[®] that AlphaNine SD, Alprolix, BeneFIX, Idelvion, Ixinity, Mononine, Rebinyn, and Rixubis are **medically necessary** when the following criteria are met:

CLINICAL POLICY**Factor IX (Human, Recombinant)****I. Initial Approval Criteria****A. Congenital Hemophilia B (must meet all):**

1. Diagnosis of congenital hemophilia B (factor IX deficiency);
2. Prescribed by or in consultation with a hematologist;
3. For AlphaNine requests only: Age \geq 17 years;
4. For Ixinity requests only: Age \geq 18 years if request is for routine prophylaxis or \geq 12 years for non-routine prophylaxis indications;
5. Request is for one of the following uses (a, b, or c):
 - a. Control and prevention of bleeding episodes;
 - b. Perioperative management;
 - c. Routine prophylaxis to prevent or reduce the frequency of bleeding episodes;
6. For routine prophylaxis requests: Request is for Alprolix, Benefix, Idelvion, Ixinity, or Rixubis, and member meets one of the following (a or b):
 - a. Member has severe hemophilia (defined as factor level of $<$ 1%);
 - b. Member has experienced at least one life-threatening or serious spontaneous bleed (*see Appendix D*);
7. Documentation of member's current body weight (in kg);
8. Dose does not exceed the FDA approved maximum recommended dose for the relevant indication.

Approval duration: 3 months (surgical/acute bleeding) or 6 months (prophylaxis)

B. Other diagnoses/indications

1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace and CP.PMN.53 for Medicaid.

II. Continued Therapy**A. Congenital Hemophilia B (must meet all):**

1. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
2. Member is responding positively to therapy;
3. Documentation of member's current body weight (in kg);
4. If request is for a dose increase, new dose does not exceed the FDA approved maximum recommended dose for the relevant indication.

Approval duration: 3 months (surgical/acute bleeding) or 6 months (prophylaxis)

B. Other diagnoses/indications (must meet 1 or 2):

1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy.

Approval duration: Duration of request or 6 months (whichever is less); or

2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace and CP.PMN.53 for Medicaid.

CLINICAL POLICY

Factor IX (Human, Recombinant)

III. Diagnoses/Indications for which coverage is NOT authorized:

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policy – CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace and CP.PMN.53 for Medicaid, or evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

FDA: Food and Drug Administration

Appendix B: Therapeutic Alternatives

Not applicable

Appendix C: Contraindications/Boxed Warnings

- Contraindication(s):
 - All products except AlphaNine SD: known history of hypersensitivity reactions, including anaphylaxis, to the product or its excipients*
 - *Including mouse or hamster protein for BeneFix, Idelvion, Ixinity, Mononine, Rebinyn, and Rixubis
 - Rixubis: disseminated intravascular coagulation, signs of fibrinolysis
- Boxed warning(s): none reported

Appendix D: General Information

- Life-threatening bleeding episodes include, but are not limited to, bleeds in the following sites: intracranial, neck/throat, or gastrointestinal.
- Serious bleeding episodes include bleeds in the following site: joints (hemarthrosis).
- Spontaneous bleed is defined as a bleeding episode that occurs without apparent cause and is not the result of trauma.

V. Dosage and Administration

Drug Name	Indication	Dosing Regimen	Maximum Dose
Factor IX, human (AlphaNine SD)	Control and prevention of bleeding episodes	Minor episodes: 20-30 IU/kg IV twice daily Moderate episodes: 25-50 IU/kg IV twice daily Major episodes: 30-50 IU/kg IV twice daily for at least 3-5 days, followed by 20 IU/kg IV twice daily Surgery: 50-100 IU/kg IV twice daily before surgery, followed	Bleeding episodes: 100 IU/kg/day Surgery: 200 IU/kg/day

CLINICAL POLICY
Factor IX (Human, Recombinant)

Drug Name	Indication	Dosing Regimen	Maximum Dose
		by the same regimen for 7-10 days thereafter	
Factor IX, human (Mononine)	Control and prevention of bleeding episodes	Minor episodes: 20-30 IU/kg IV every 24 hours Major trauma or surgery: 75 IU/kg IV every 18-30 hours	Minor episodes: 30 IU/kg/day Major trauma or surgery: 750 IU/kg/18 hours
Factor IX, recombinant (Alprolix)	Control and prevention of bleeding episodes, perioperative management	Minor and moderate episodes: 30-60 IU/dL/kg IV every 48 hours if there is further evidence of bleeding after the first dose Major episodes: 80-100 IU/dL/kg IV initially; consider a repeat dose after 6-10 hours and then every 24 hours for the first 3 days. May extend to dosing every 48 hours or longer after the first 3 days Minor surgery: 50-80 IU/dL/kg IV initially followed by every 24-48 hours until bleeding stops and healing is achieved Major surgery: 60-100 IU/dL/kg IV initially; consider a repeat dose after 6-10 hours and then every 24 hours for the first 3 days. May extend to dosing every 48 hours or longer after the first 3 days	Bleeding episodes: 100 IU/dL/kg/dose Surgery: 100 IU/dL/kg/dose
	Routine prophylaxis	50 IU/dL/kg IV once weekly or 100 IU/dL/kg IV once every 10 days (start with 60 IU/kg once weekly for < 12 years)	100 IU/dL/kg/dose
Factor IX, recombinant (BeneFIX)	Control and prevention of bleeding episodes,	Minor episodes: 20-30 IU/dL/kg IV every 12-24 hours	200 IU/dL/kg/day

CLINICAL POLICY
Factor IX (Human, Recombinant)

Drug Name	Indication	Dosing Regimen	Maximum Dose
	perioperative management	Moderate episodes: 25-50 IU/dL/kg IV every 12-24 hours Major episodes: 50-100 IU/dL/kg IV every 12-24 hours Surgery: 50-100 IU/dL/kg IV every 12-24 hours	
	Routine prophylaxis	100 IU/kg once weekly	100 IU/kg/dose
Factor IX, recombinant (Idelvion)	Control and prevention of bleeding episodes, perioperative management	Minor and moderate episodes: 30-60 IU/dL/kg IV every 48-72 hours Major episodes: 60-100 IU/dL/kg IV every 48-72 hours until bleeding stops and healing is achieved; maintenance dose is weekly Minor surgery: 50-80 IU/dL/kg IV every 48-72 hours until healing is achieved Major surgery: 60-100 IU/dL/kg IV every 48-72 hours until bleeding stops and healing is achieved; maintenance dose is 1-2 times per week	Bleeding episodes: 100 IU/dL/kg/48 hours Surgery: 80 IU/dL/kg/48 hours
	Routine prophylaxis	≥ 12 years of age: 25-40 IU/kg IV every 7 days followed by 50-75 IU/kg IV every 14 days once well-controlled < 12 years of age: 40-55 IU/kg IV every 7 days	55 IU/kg/week
Factor IX, recombinant (Ixinity)	Control and prevention of bleeding episodes, perioperative management	Minor episodes: 30-60 IU/dL/kg IV every 24 hours Moderate episodes: 40-60 IU/dL/kg IV every 24 hours Major episodes: 60-100 IU/dL/kg IV every 12-24 hours	Bleeding episodes: 102 IU/dL/kg/dose Surgery: 81.6 IU/dL/kg/dose

CLINICAL POLICY
Factor IX (Human, Recombinant)

Drug Name	Indication	Dosing Regimen	Maximum Dose
		<p>Minor surgery: 50-80 IU/dL/kg IV pre-operatively followed by 30-80 IU/dL/kg every 24 hours</p> <p>Major surgery: 60-80 IU/dL/kg IV pre-operatively followed by 40-60 IU/dL/kg IV every 8-24 hours for 1-3 days or 30-50 IU/dL/kg IV every 8-24 hours for 4-6 days or 20-40 IU/dL/kg IV every 8-24 hours for 7-14 days</p>	
	Routine prophylaxis	40 to 70 IU/kg IV twice weekly	140 IU/kg/week
Factor IX, recombinant (Rixubis)	Control and prevention of bleeding episodes, perioperative management	<p>Minor episodes: 20-30 IU/dL/kg IV every 12-24 hours until healing is achieved</p> <p>Moderate episodes: 25-50 IU/dL/kg IV every 12-24 hours until bleeding stops and healing is achieved</p> <p>Major episodes: 50-100 IU/dL/kg IV every 12-24 hours until bleeding stops and healing is achieved</p> <p>Minor surgery: 30-60 IU/dL/kg IV every 24 hours until healing is achieved</p> <p>Major surgery: 80-100 IU/dL/kg IV every 8-24 hours until bleeding stops and healing is achieved</p>	100 IU/dL/kg/dose
	Routine prophylaxis	<p>≥ 12 years of age: 40-60 IU/kg IV twice weekly</p> <p>< 12 years of age: 60-80 IU/kg IV twice weekly</p>	80 IU/kg/dose
Factor IX, recombinant,	On-demand treatment and	40 IU/kg body weight for minor and moderate bleeds, and 80	80 IU/kg/dose

CLINICAL POLICY
Factor IX (Human, Recombinant)

Drug Name	Indication	Dosing Regimen	Maximum Dose
glycopegylated (Rebinyn)	control of bleeding episodes	IU/kg body weight for major bleeds. Additional doses of 40 IU/kg can be given	
	Perioperative management of bleeding	Pre-operative dose of 40 IU/kg body weight for minor surgery, and 80 IU/kg body weight for major surgery. As clinically needed for the perioperative management of bleeding, repeated doses of 40 IU/kg (in 1-3 day intervals) within the first week after major surgery may be administered. Frequency may be extended to once weekly after the first week until bleeding stops and healing is achieved.	80 IU/kg pre-operatively; 40 IU/kg/dose after surgery

VI. Product Availability

Drug Name	Availability
Factor IX, human (AlphaNine SD)	Vials: 500, 1,000, 1,500 IU
Factor IX, human (Mononine)	Vials: 500, 1,000 IU
Factor IX, recombinant (Alprolix)	Vials: 250, 500, 1,000, 2,000, 3,000, 4,000 IU
Factor IX, recombinant (BeneFIX)	Vials: 250, 500, 1,000, 2,000, 3,000 IU
Factor IX, recombinant (Idelvion)	Vials: 250, 500, 1,000, 2,000, 3500 IU
Factor IX, recombinant (Ixinity)	Vials: 250, 500, 1,000, 1,500, 2,000, 3,000 IU
Factor IX, recombinant (Rixubis)	Vials: 250, 500, 1,000, 2,000, 3,000 IU
Factor IX, recombinant, glycopegylated (Rebinyn)	Vials: 500, 1,000, 2,000 IU

VII. References

1. Alphanine SD Prescribing Information. Los Angeles, CA: Grifols Biologicals, Inc.; June 2018. Available at: www.alphaninesd.com. Accessed November 23, 2021.
2. Alprolix Prescribing Information. Cambridge, MA: Biogen Idec, Inc.; October 2020. Available at: www.alprolix.com. Accessed November 23, 2021.
3. BeneFix Prescribing Information. Philadelphia, PA: Wyeth Pharmaceuticals, Inc.; September 2021. Available at: www.benefix.com. Accessed November 23, 2021.
4. Idelvion Prescribing Information. Kankakee, IL: CSL Behring LLC; July 2021. Available at: www.idelvion.com. Accessed November 23, 2021.
5. Ixinity Prescribing Information. Berwyn, PA: Aptevo BioTherapeutics LLC; February 2021. Available at: www.ixinity.com. Accessed November 23, 2021.

CLINICAL POLICY

Factor IX (Human, Recombinant)

6. Mononine Prescribing Information. Kankakee, IL: ZLB Behring, LLC; December 2018. Available at: [www. http://labeling.csllabehring.com/PI/US/Mononine/EN/Mononine-Prescribing-Information.pdf](http://labeling.csllabehring.com/PI/US/Mononine/EN/Mononine-Prescribing-Information.pdf). Accessed November 23, 2021.
7. Rebinyn Prescribing Information. Plainsboro, NJ: Novo Nordisk; June 2020. Available at: www.rebinyn.com. Accessed November 23, 2021.
8. Rixubis Prescribing Information. Westlake Village, CA: Baxalta US Inc.; June 2020. Available at: <http://www.rixubis.com>. Accessed November 23, 2021.
9. Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia. *Haemophilia*. Jan 2013; 19(1): e1-47.
10. Medical and Scientific Advisory Council (MASAC) of the National Hemophilia Foundation (NHF): Database of treatment guidelines. Available at <https://www.hemophilia.org/Researchers-Healthcare-Providers/Medical-and-Scientific-Advisory-Council-MASAC/MASAC-Recommendations>. Accessed November 30, 2020.

Coding Implications

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPCS Codes	Description
J7194	Factor IX complex, per IU
J7195	Injection, factor IX (antihemophilic factor, recombinant) per IU, not otherwise specified
J7200	Injection, factor IX, (antihemophilic factor, recombinant), Rixubis, per IU
J7201	Injection, factor IX, FC fusion protein (recombinant), per IU
J7202	Injection, factor IX, albumin fusion protein, (recombinant), Idelvion, per IU

Reviews, Revisions, and Approvals	Date	P&T Approval Date
1Q18 annual review: - Converted to new template - Added Idelvion to the policy under the same coverage criteria as the other recombinant factor IX agents. - Specified routine prophylaxis indication is only for certain agents, per package labeling for those agents. - Added age limit for AlphaNine per package labeling - References reviewed and updated.	11.28.17	02.18
1Q 2019 annual review: added HIM-Medical Benefit; no significant changes; added Rebinyn; references reviewed and updated.	11.08.18	02.19
RT4: added new strength of Idelvion 3,500 IU.	06.21.19	
1Q 2020 annual review: no significant changes; added HIM line of business; references reviewed and updated.	11.27.19	02.20

CLINICAL POLICY
Factor IX (Human, Recombinant)

Reviews, Revisions, and Approvals	Date	P&T Approval Date
Added routine prophylaxis-specific requirement for severe hemophilia classification or at least one life-threatening or serious spontaneous bleed for classification of non-severe hemophilia; added requirement for prescriber attestation of not partaking in contact sports. RT4: updated Benefix indication of routine prophylaxis.	07.21.20	08.20
Removed requirement for prescriber attestation of not partaking in contact sports.	10.01.20	11.20
1Q 2021 annual review: added Commercial line of business; added requirement for documentation of body weight for calculation of appropriate dosage; references to HIM.PHAR.21 revised to HIM.PA.154; references reviewed and updated. RT4: added newly approved indication for Ixinity for routine prophylaxis.	11.30.20	02.21
RT4: revised routine prophylaxis indications for Benefix and Ixinity to limit use to patients aged 16 and older or 18 and older, respectively, in accordance with FDA removal of use for younger patients from the Benefix and Ixinity labels.	05.12.21	
1Q 2022 annual review: no significant changes; lower age limit on BeneFIX for routine prophylaxis was removed to reflect the FDA’s reversal on the age limit that had previously been applied for patients 16 years and older; references reviewed and updated.	11.23.21	02.22

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

CLINICAL POLICY

Factor IX (Human, Recombinant)

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note: For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2016 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene[®] and Centene Corporation[®] are registered trademarks exclusively owned by Centene Corporation.